Do you want to read an article? Please log in or register.
Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
Migraine and Headache
Related content
Migraine and HeadacheAnxiety and Depression
Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study
Headache
Lipton RB, Cohen JM, Galic M, Seminerio MJ, Yeung PP, Aycardi E, Bigal ME, Bibeau K, Buse DC
doi: 10.1111/head.14097
RECOMMENDED
Migraine and Headache
Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Headache
Smitherman TA, Tietjen GE, Schuh K, Skljarevski V, Lipsius S, D'Souza DN, Pearlman EM
doi: 10.1111/head.13970
RECOMMENDED
Migraine and Headache
Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
★ 2
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Cephalalgia
Lipton RB, Tepper SJ, Silberstein SD, Kudrow D, Ashina M, Reuter U, Dodick DW, Zhang F, Rippon GA, Cheng S, Mikol DD
doi: 10.1177/0333102420973994
Migraine and Headache
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study
Headache
Spierings ELH, Ning X, Ramirez Campos V, Cohen JM, Barash S, Buse DC
doi: 10.1111/head.14196
Migraine and Headache
Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine
Cephalalgia.
Brandes JL, Kudrow D, Yeung PP, Sakai F, Aycardi E, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y
doi: 10.1177/0333102419885905.
Migraine and Headache
Living with chronic migraine: a qualitative study on female patients' perspectives from a specialised headache clinic in Spain
BMJ Open.
Palacios-Ceña D, Neira-Martín B, Silva-Hernández L, Mayo-Canalejo D, Florencio LL, Fernández-de-Las-Peñas C, García-Moreno H, García-Azorín D, Cuadrado ML
doi: 10.1136/
Migraine and Headache
Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache
Headache
Kudrow D, Andrews JS, Rettiganti M, Oakes T, Bardos J, Gaul C, Riesenberg R, Wenzel R, Kuruppu D, Martinez J
doi: 10.1111/head.14011
RECOMMENDED
Migraine and Headache
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response
★ 2
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Cephalalgia.
Brandes JL, Diener HC, Dolezil D, Freeman MC, McAllister PJ, Winner P, Klatt J, Cheng S, Zhang F, Wen S, Ritter S, Lenz RA, Mikol DD
doi: 10.1177/0333102419894559.
Migraine and Headache
Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine
Cephalalgia
Dodick DW, Doty EG, Aurora SK, Ruff DD, Stauffer VL, Jedynak J, Dong Y, Pearlman EM
doi: 10.1177/0333102420966658